Levin O S, Batukaeva L A, Anikina M A, Iunishchenko N A
Kafedra nevrologii Rossiĭskoĭ meditsinskoĭ akademii poslediplomnogo obrazovaniia, Moskva.
Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(11):42-6.
An open 10-day study of treatment effect of cereton in comparison to piracetam has been conducted. Cereton was used in 40 patients (main group) in dosage 1000 mg, piracetam - in 20 patients (control group) in dosage 2000 mg. Both drugs were used intravenous in drops in 200 ml of physiologic saline along with antiparkinsonian medications. Patient's state was assessed with a battery of psychometric scales and neuropsychological tests as well as with instruments for measuring intensity of parkinsonian symptoms, side-effects and quality of life. Marked and moderate improvement of cognitive functions was found in patients of the main group compared to the control one (40% and 25%, respectively, p<0,05). Deterioration of cognitive functions was seen less often in the main group than in the control group (5% and 15%, respectively, p<0,05). Cereton was well-tolerated by patients. Side effects (brief and short-term) were found only in 6 (15%) patients.
开展了一项为期10天的开放性研究，比较了塞雷通与吡拉西坦的治疗效果。40名患者（主要组）使用塞雷通，剂量为1000毫克；20名患者（对照组）使用吡拉西坦，剂量为2000毫克。两种药物均与抗帕金森病药物一起静脉滴注于200毫升生理盐水中。通过一系列心理测量量表、神经心理学测试以及测量帕金森病症状强度、副作用和生活质量的仪器对患者状态进行评估。与对照组相比，主要组患者的认知功能有显著和中度改善（分别为40%和25%，p<0.05）。主要组认知功能恶化的情况比对照组少见（分别为5%和15%，p<0.05）。患者对塞雷通耐受性良好。仅6名（15%）患者出现副作用（短暂且短期）。
